Key Takeaway: The TORREY study has been completed, revealing that Gossamer Bio's seralutinib (GB002) significantly improved hemodynamics, right heart structure, and function. The topline data, reported in December 2022, also indicated positive changes in biomarkers associated with pulmonary arterial hypertension (PAH) severity. These findings suggest potential benefits for patients with PAH.
Price reaction · baseline $0.9001 (2024-08-20T17:31:00.000Z) · hit during market hours · 1 other GOSS headline(s) in the window, move may be shared
day 0 close · peak
+3.3%
Market Sentiment Analysis
POSITIVE FACTORS
Statistically significant impact on hemodynamics.
Improvement in right heart structure and function.
Positive results on important biomarkers of PAH severity.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Full Press Release Details
The TORREY study has been completed and Gossamer Bio reported topline data in December 2022, showing that seralutinib (AKA GB002) had a statistically significant impact on hemodynamics (PVR), right heart structure and function, and important biomarkers of PAH disease severity (e.g., NT-proBNP). Read more about the TORREY results here .
TORREY Study on clinicaltrials.gov 2021 PHPN Symposium Presentation GOSS-PHAware Podcast Episode #2 Request More Information About TORREY
Frequently Asked Questions
What were the results of the TORREY study?
The TORREY study showed seralutinib had a significant impact on hemodynamics and biomarkers of PAH.
What is seralutinib?
Seralutinib, also known as GB002, is a treatment investigated for pulmonary arterial hypertension.
When was the TORREY study completed?
The TORREY study was completed and topline data was reported in December 2022.
What is the significance of NT-proBNP in the study?
NT-proBNP is a biomarker used to assess the severity of pulmonary arterial hypertension.